-+ 0.00%
-+ 0.00%
-+ 0.00%

IPO News | Binhui Biotech's Hong Kong stock IPO and “full circulation” of domestic unlisted shares were registered by the China Securities Regulatory Commission

Zhitongcaijing·09/04/2026 10:41:04
Listen to the news

The Zhitong Finance App learned that on September 4, the International Cooperation Department of the China Securities Regulatory Commission issued the “Notice on the “Full Circulation” of Overseas Issuance and Domestic Unlisted Shares of Wuhan Binhui Biotechnology Co., Ltd. The company intends to issue no more than 38,102,600 overseas listed common shares and list them on the Hong Kong Stock Exchange. The 54 shareholders of the company intend to convert a total of 150,933,379 domestic unlisted shares into overseas listed shares and list them for circulation on the Hong Kong Stock Exchange.

3b86cd97-66cb-45eb-a24b-e7e571a22449.png

According to the prospectus, the company is a biotechnology company for oncolytic virus therapy based in China, dedicated to the discovery, development and commercialization of cancer immunotherapy. The company developed the core product BS001 (OH2 injection) and two key products in-house. As of the last practical date (March 27, 2026), the company's pipeline includes two clinical-stage drug candidates (i.e. BS001 and BS006) and two pre-clinical stage drug candidates (i.e. BR003 and BS051).

828b765c-af68-41eb-80a7-ef58f08311d1.png